Skip to main content

Table 3 Treatment outcome (n = 40, 100%)

From: To coagulate, ligate, or both: a randomized study comparing the safety and efficacy of two endoscopic approaches for managing gastric antral vascular ectasia in cirrhotic patients

Comparative factors

Group I: combined therapy group

Group II: EBL group

P value

Mean/count

%/±SD

Mean/count

%/±SD

Treatment sessions

 Mean number of treatment sessions

3.25

± 1.07

1.95

± 0.76

0.001*

 Mean number of banding sessions

1.5

± 1.5

1.95

± 0.76

0.034*

 Mean bands number used

8.3

± 3.53

11.35

± 5.44

0.042*

 Recurrence of bleeding from GAVE (after 6 months of follow-up)

3

15%

2

10%

0.676

 Cessation of bleeding (after 6 months of follow-up)

17

85%

18

90%

 

Treatment outcomes

     

 Hemoglobin (g/dl) at baseline

6.86

± 1.25

7.71

± 1.66

0.074

 Hospitalization at baseline

1.60

± 1.00

1.50

± 1.05

0.641

 Blood transfusion at baseline

3.90

± 2.55

3.20

± 2.24

0.360

 Hemoglobin (g/dl)(6 months follow-up)

9.78

± 1.68

10.04

± 1.93

0.646

 Hospitalization (6 months follow-up)

0.40

± 0.88

0.40

± 0.82

0.794

 Bood transfusion (6 months follow-up)

0.70

± 1.98

0.95

± 1.88

0.462

 The mean changes in hemoglobin (g/dl)

2.92

± 1.50

2.33

± 1.74

0.258

 The mean changes in hospitalization

-1.2

± 1.24

− 1.10

± 0.91

0.773

 The mean changes in transfusion

-3.20

± 2.28

− 2.25

± 1.52

0.130

  1. Unless otherwise stated numerical data are expressed as mean (SD). Statistically significant values are in bold
  2. P > 0.05 = not significant, *P < 0.05 = significant, **P < 0.01 = highly significant. Baseline transfusion and hospitalization applies to the last 6 months preceding recruitment